Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Korro Bio, Inc. terminated Sublease Agreement with Saliogen Therapeutics, Inc. valued at No payments or costs (effective 2024-01-31).
- Action
- termination
- Agreement
- lease
- Counterparty
- Saliogen Therapeutics, Inc.
- Value
- No payments or costs
- Effective
- 2024-01-31
Exact text from the filing
Also on August 11, 2023, the Company entered into a Sublease Termination Agreement with Saliogen Therapeutics, Inc. (“Subtenant”), pursuant to which the parties agreed to terminate that certain Sublease Agreement, by and between the Company and Subtenant, dated as of July 8, 2022 (the “Sublease”), on January 31, 2024 (the “Sublease Termination Agreement”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Korro Bio, Inc. terminated Indenture of Lease (Master Lease) with LS 75 Hayden LLC valued at No payments or costs (effective 2024-01-31).
- Action
- termination
- Agreement
- lease
- Counterparty
- LS 75 Hayden LLC
- Value
- No payments or costs
- Effective
- 2024-01-31
Exact text from the filing
On August 11, 2023, Frequency Therapeutics, Inc. (the “Company”) entered into a Termination Agreement with LS 75 Hayden LLC (“Landlord”) for certain premises located at 75 Hayden Avenue, Lexington, Massachusetts (the “Lease Termination Agreement”). The Lease Termination Agreement provides that the Indenture of Lease (the “Master Lease”), dated as of January 7, 2020, by and between the Company and the Landlord will terminate on January 31, 2024.
View on SEC.gov